GlaxoSmithKline Biologicals, s.a. Patent applications |
Patent application number | Title | Published |
20160108094 | IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS - Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium. | 04-21-2016 |
20160082098 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 03-24-2016 |
20160067326 | MUTANT BACTERIA FOR PRODUCTION OF GENERALIZED MODULES FOR MRMBRANE ANTIGENS - Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable | 03-10-2016 |
20160051658 | NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria | 02-25-2016 |
20160039887 | MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870 - Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870. | 02-11-2016 |
20160030546 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 02-04-2016 |
20160030545 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 02-04-2016 |
20160024157 | HAEMOPHILUS INFLUENZAE TYPE B - Polypeptides comprising various amino acid sequences derived from | 01-28-2016 |
20150322116 | PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS - An effective | 11-12-2015 |
20150315225 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 11-05-2015 |
20150313985 | IMMUNOGENIC COMPOSITION COMPRISING ELEMENTS OF C. DIFFICILE CDTB AND/OR CDTA PROTEINS - The present invention relates to immunogenic compositions comprising isolated | 11-05-2015 |
20150273047 | VACCINE - The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus (IPV) is provided, which can maintain an adequate or improved level of protection against polio. | 10-01-2015 |
20150273044 | METHODS OF INDUCING AN IMMUNE RESPONSE WITH COMPOSITIONS COMPRISING A NEISSERIA MENINGITIDIS 741 PROTEIN - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 10-01-2015 |
20150273036 | NON-CROSS-LINKED ACELLULAR PERTUSSIS ANTIGENS FOR USE IN COMBINATION VACCINES - The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed. | 10-01-2015 |
20150258188 | BACTERIAL OUTER MEMBRANE VESICLES - Existing methods of meningococcal OMV preparation involve the use of detergent during disruption of the bacterial membrane. According to the invention, membrane disruption is performed substantially in the absence of detergent. The resulting OMVs which retain important bacterial immunogenic components, particularly (i) the protective NspA surface protein, (ü) protein NMB2132 and (iii) protein NMB 1870. A Typical process involves the following steps: (a) treating bacterial cells in the substantial absence of detergent; (b) centrifuging the composition from step (a) to separate the outer membrane vesicles from treated cells and cell debris, and collecting the supernatant; (c) performing a high speed centrifugation of the supernatant from step (b) and collecting the outer membrane vesicles in a pellet; (d) re-dispersing the pellet from step (c) in a buffer; (e) performing a second high speed centrifugation in accordance with step (c), collecting the outer membrane vesicles in a pellet; (f) re-dispersing the pellet from step (e) in an aqueous medium. | 09-17-2015 |
20140323731 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES - The compounds of the subject invention are adjuvant molecules that comprise an imidazoquinoline molecule covalently linked to a phospho- or phosphonolipid group. The compounds of the invention have been shown to be inducers of interferon-a, IL-12 and other immunostimulatory cytokines and possess an improved activity profile in comparison to known cytokine inducers when used as adjuvants for vaccine antigens. | 10-30-2014 |
20140314802 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 10-23-2014 |
20140294849 | COMPOSITIONS AND USES - The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease. | 10-02-2014 |
20140243513 | Methods for the Production of 3-O-Deactivated-4'-Monophosphoryl Lipid A (3D-MLA) - Herein is disclosed a method for producing lipopolysaccharide (LPS), comprising: (a) growing a culture of a deep rough mutant bacterial strain in a medium; (b) maintaining the culture in stationary phase for at least about 5 hr; (c) harvesting, cells from the culture; and (d) extracting LPS from the cells. The method allows for the production of an LPS which can be used to produce a 3-O-deacylated monophosphoryl lipid A (3D-MLA) having at least about 20 mol % of the hexaacyl congener group. | 08-28-2014 |
20140242635 | Fermentation Process for the Production of Diphtheria Toxin - The present invention relates to a fermentation process comprising a fermentation step of growing a strain of | 08-28-2014 |
20140242112 | NOVEL VACCINE - The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) 7 agonist in an orally (e.g. sublingually) administered composition. | 08-28-2014 |
20140234424 | PRAME PURIFICATION - Methods and processes for the purification of PRAME are provided. In particular, methods for reducing the aggregation of PRAME during a diluent exchange from diluent A to diluent B comprising: (i) adding a polyanionic compound to diluent A prior to or contemporaneously with the exchange; and (ii) exchanging protein from diluent A to diluent B are provided. Compositions produced by the method are also provided. | 08-21-2014 |
20140234403 | LIPOSOME PRODUCTION USING ISOPROPANOL - Provided are compositions and methods for producing a lipidic film. The method comprises the steps of: (i) dissolving a lipid mix in isopropanol to form a homogeneous mix; and (ii) removing the solvent from the homogeneous mix to form a lipidic film, wherein the lipid mix comprises a lipid and cholesterol. | 08-21-2014 |
20140234399 | HIV VACCINE - The present invention relates to immunogenic compositions comprising HIV-1 antigens and uses thereof in the prevention and/or treatment of HIV-1. In particular, the invention relates to the use of HIV-1 antigens from one clade in the prevention and/or treatment of disease associated with HIV-1 infection from a heterologous HIV-1 clade. | 08-21-2014 |
20140205652 | NOVEL METHOD AND COMPOSITIONS - The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants. | 07-24-2014 |
20140205634 | TREATMENT OF STREPTOCOCCAL INFECTIONS - Methods of treating a | 07-24-2014 |
20140193481 | STABILISED VACCINE COMPOSITION - A component for a HIV vaccine comprising:
| 07-10-2014 |
20140193451 | IMMUNOGENIC COMPOSITION - The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and/or PhtD, vaccines comprising the immunogenic compositions and their use in medicine. | 07-10-2014 |
20140186390 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 07-03-2014 |
20140186389 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 07-03-2014 |
20140105992 | VACCINE - The present provide vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed on to a particle of metal salt and the resulting particle is essentially devoid of antigen. | 04-17-2014 |
20140105927 | IMMUNOGENIC COMPOSITION - The present invention relates to an immunogenic composition comprising
| 04-17-2014 |
20140105926 | IMMUNOGENIC COMPOSITION - The present invention relates to immunogenic compositions comprising one or more | 04-17-2014 |
20140099339 | VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE - The present invention relates to a combination of 2 or more | 04-10-2014 |
20140093529 | IMMUNOGENIC COMPOSITION - The present invention relates to fusion proteins comprising fragments of toxin A and toxin B from | 04-03-2014 |
20140086948 | TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 03-27-2014 |
20140072622 | VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE - The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated | 03-13-2014 |
20140056967 | VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of | 02-27-2014 |
20140056934 | FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A - The present invention relates to compositions comprising | 02-27-2014 |
20140050776 | NOVEL METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION - The present invention is directed to methods of preventing reactivation of active and latent | 02-20-2014 |
20140050758 | FERMENTATION PROCESS - The present invention provides a process for periplasmic expression of a bacterial toxoid comprising the steps of: | 02-20-2014 |
20140037680 | NOVEL METHOD - This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) through maternal immunization using recombinant respiratory syncytial virus (RSV) antigens to reduce the incidence or severity of RSV infection in young infants. | 02-06-2014 |
20140030342 | PROCESS FOR PRODUCING AN IMMUNOGENIC COMPOSITION CONTAINING TETANUS TOXOID - The present invention relates to the field of vaccines for protecting against tetanus, and in particular processes for the production of vaccines comprising tetanus toxoid adsorbed onto aluminium salts. Processes are provided whereby tetanus toxoid is absorbed onto aluminium salt adjuvant having defined characteristics for optimal results. | 01-30-2014 |
20140030318 | PURIFICATION PROCESS - The present disclosure concerns methods for producing purified | 01-30-2014 |
20130344103 | CONJUGATION PROCESS - The present invention relates to a process for conjugation of an antigen. | 12-26-2013 |
20130287809 | MYCOBACTERIUM ANTIGENIC COMPOSITION - Immunogenic compositions comprising an Rv1196 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided. | 10-31-2013 |
20130280322 | VACCINE - The present invention provides methods and compositions for the treatment of HIV-1 infected subjects. The invention relates in particular to enhancing the immune response of an infected subject and to stabilising or reducing the viral load of an infected subject. | 10-24-2013 |
20130280289 | MYCOBACTERIUM ANTIGENIC COMPOSITION - Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided. | 10-24-2013 |
20130251745 | VACCINE - The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventors disclose that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem. | 09-26-2013 |
20130224266 | IMMUNOGENIC COMPOSITION - The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a | 08-29-2013 |
20130216614 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NUEROLOGIC DISORDERS - The present invention relates to methods and compositions for preventing and reducing amyloid deposition in a subject by administering to the subject a composition containing aTLR4 agonist free of endotoxin, where the composition does not contain beta amyloid. | 08-22-2013 |
20130171188 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example | 07-04-2013 |
20130123472 | NOVEL ANTIGEN BINDING PROTEINS - Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof. | 05-16-2013 |
20130095135 | PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE PRODUCTION OF A VIRUS IN CELL CULTURE - The present invention relates to improved processes for the production of viruses, in particular, viruses for use in medicine (for example vaccination or gene therapy). | 04-18-2013 |
20130089573 | NOVEL PROCESS - The present invention provides processes for the production of a submicron oil in water emulsion comprising the steps of preparing a submicron oil in water emulsion; pre-filtering the oil in water emulsion through a first sterile grade filter and again filtering the oil in water emulsion through a second sterile grade filter. | 04-11-2013 |
20130084309 | PROCESS FOR THE PREPARATION OF O/W EMULSION - The present invention provides a process for the production of an oil in water emulsion comprising the steps of: a) dissolving a surfactant in a volume of water or aqueous solution to produce a surfactant solution; and b) diluting the surfactant solution in a volume of water or aqueous solution greater than the volume of the surfactant solution to produce an aqueous phase. | 04-04-2013 |
20130079395 | NOVEL PROCESS - The present invention provides a process for the production of an oil in water emulsion comprising the step of a) introducing an oil phase into a mixing device by applying a positive pressure in the oil phase containing tank. | 03-28-2013 |
20130066064 | NOVEL PROCESS - A single-phase LPS extraction composition comprising water, an alcohol and a further organic solvent, where the amount of water is between about 0.8 to 1.2% (v/v). | 03-14-2013 |
20120328622 | NOVEL COMPOUNDS - The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 12-27-2012 |
20120244189 | TREATMENT OF INFECTIONS - The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy. | 09-27-2012 |
20120189654 | VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 07-26-2012 |
20120135028 | VACCINE - The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided. | 05-31-2012 |
20120093921 | IMMUNOGENIC COMPOSITIONS HAVING LOW SODIUM CHLORIDE CONCENTRATION - Immunogenic compositions comprising an antigen, wherein the concentration of sodium chloride or the ionic strength of the composition is less than 100 mM, and their use in medicine, are provided. | 04-19-2012 |
20120077268 | ANIMAL-FREE CELL CULTURE METHOD - The present invention relates to a process for culturing animal cells, e.g., human, diploid anchorage-dependent cells, in the absence of exogenous components of primary animal origin. In particular, the invention provides cell culture media substantially free of exogenous components of primary and secondary animal origin which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal cells using a protease of non-animal origin for passaging cells. | 03-29-2012 |
20120064120 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 03-15-2012 |
20120064119 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 03-15-2012 |
20120045469 | VACCINE - The present invention provides an immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising an oil-in-water emulsion. | 02-23-2012 |
20120039993 | Detection of Gene Expression - An oligonucleotide, primer or probe comprises the nucleotide sequence of any of SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 61, 62 or 63. The oligonucleotide, primer or probe is useful for the detection of the methylation status of a gene. The oligonucleotides find application in the diagnosis and treatment of cancer. | 02-16-2012 |
20120039942 | OUTER MEMBRANE VESICLES AND USES THEREOF - The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection. | 02-16-2012 |
20120039933 | METHODS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE - The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation. | 02-16-2012 |
20120029437 | KITS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE - The invention relates to a pharmaceutical kit for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation. | 02-02-2012 |
20120027800 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 02-02-2012 |
20110300206 | VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of | 12-08-2011 |
20110282061 | Lipidated Imidazoquinoline Derivatives - The compounds of the subject invention are adjuvant molecules that comprise a imidazoquinoline molecule covalently linked to a phospho- or phosphonolipid group. The compounds of the invention have been shown to be inducers of interferon-a, IL-12 and other immunostimulatory cytokines and possess an improved activity profile in comparison to known cytokine inducers when used as adjuvants for vaccine antigens. | 11-17-2011 |
20110189229 | VACCINE AGAINST HPV - The use of HPV 16 and HPV 18 virus like particles (VLPs) together with a pharmaceutically acceptable excipient, in a vaccine for the prevention of human papillomavirus related disease or infection, wherein the vaccine is formulated for administration according to a two dose regimen consisting of a first dose and a second dose. | 08-04-2011 |
20110129475 | BASB 205 POLYPEPTIDES AND POLYNUCLEOTIDES FROM HAEMOPHILUS INFLUENZAE - The invention provides BASB205 polypeptides and polynucleotides encoding BASB205 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 06-02-2011 |
20110104260 | VACCINE AGAINST VARICELLA ZOSTER VIRUS - Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed | 05-05-2011 |
20110070268 | Method - Methods for characterisation of patients as responders or non-responders to therapy based on differential expression of one or more genes are provided. Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods of treatment are also provided. The kits and methods relate to the treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from MAGE expressing tumours. | 03-24-2011 |
20110045059 | VACCINE AGAINST VARICELLA ZOSTER VIRUS - Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed | 02-24-2011 |
20110033500 | VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB | 02-10-2011 |
20110008385 | Immunogenic composition - The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from | 01-13-2011 |
20100322959 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Methods of using and processes to make an immunogenic composition are also described. | 12-23-2010 |
20100291137 | METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN - The present invention provides an isolated refolded NspA protein, and a method of preparing it. | 11-18-2010 |
20100285465 | Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis - The present invention relates to a method of LOS molecular typing of a | 11-11-2010 |
20100272788 | VACCINES FOR MALARIA - The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, | 10-28-2010 |
20100203057 | NOVEL COMPOUNDS - The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 08-12-2010 |
20100196409 | BASB006 POLYPEPTIDES FROM NEISSERIA MENINGITIDIS AND IMMUNOGENIC COMPOSITIONS THEREOF - The invention provides BASB006 polypeptides and polynucleotides encoding BASB006 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 08-05-2010 |
20100184139 | BASB082 polynucleotides - The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 07-22-2010 |
20100166783 | METHOD - Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods are provided. The gene expression profiles, microarrays, and new diagnostic kits and methods find use in the treatment of specific populations of cancer patients suffering from MAGE expressing tumours, the populations characterised by their gene expression profile. | 07-01-2010 |
20100150998 | VACCINES FOR MALARIA - The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers:
| 06-17-2010 |
20100143412 | BASB027 PROTEINS AND GENES FROM MORAXELLA CATARRHALIS, ANTIGENS, ANTIBODIES, AND USES - The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 06-10-2010 |
20100075378 | MORAXELLA CATARRHALIS BASB115 POLYPEPTIDES - The invention provides BASB115 polypeptides and polynucleotides encoding BASB115 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 03-25-2010 |
20100040647 | VACCINE - The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided | 02-18-2010 |
20100029912 | Fusion Protein - Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells. | 02-04-2010 |
20100021503 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from | 01-28-2010 |
20090285879 | Malaria prime/boost vaccines - Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from | 11-19-2009 |
20090028828 | Rotavirus Vaccine Inducing Heterotypic Cross Protection - The invention provides a method of inducing an immune response against rotavirus strain, the method comprising administering to a subject a composition comprising an attenuated rotavirus strain of a GxPy type, said composition generating an immune response against a rotavirus strain which is neither a Gx nor a Py type. | 01-29-2009 |
20090022755 | VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of | 01-22-2009 |
20090017072 | Vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent | 01-15-2009 |
20090017059 | Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates - The present invention discloses an immunogenic composition comprising | 01-15-2009 |
20080311146 | Immunogenic Composition - The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain. | 12-18-2008 |
20080305127 | Conjugate Vaccines - The invention provides vaccines against | 12-11-2008 |
20080254034 | BASB119 Polypeptide and Polynucleotide from Moraxella Catarrhalis - The invention provides BASB119 polypeptides and polynucleotides encoding BASB119 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 10-16-2008 |
20080249013 | Vaccines - Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung, colon, colorectal and breast cancer. | 10-09-2008 |
20080226637 | Haemophilus influenzae BASB206 gene and protein - This invention relates to polynucleotides, (herein referred to as “BASB206 polynucleotide(s)”), polypeptides encoded by them (referred to herein as “BASB206” or “BASB206 polypeptide(s)”), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the invention relates to diagnostic assays for detecting infection of certain pathogens. | 09-18-2008 |
20080219986 | Polynucleotides and polypeptides BASB033 from neisseria meningitidis and their uses - The invention provides BASB033 polypeptides and polynucleotides encoding BASB033 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 09-11-2008 |